Physeon Positive Clinical Trial Results for its Veinplicity® Device to be Published in The Journal of Vascular Access
01. April 2019 09:00 ET
|
Physeon
SCHAFFHAUSEN, Switzerland, April 01, 2019 (GLOBE NEWSWIRE) -- Physeon GmbH, (“Physeon” or the “Company”), a leading developer of medical technology products for venous access, today announced that...
Physeon’s Veinplicity Device Featured on ABC Affiliate KSTP Channel 5
14. Februar 2019 13:42 ET
|
Physeon
SCHAFFHAUSEN, Switzerland, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Physeon GmbH, (“Physeon” or the “Company”), a leading developer of medical technology products for venous access, today announced that...
Mayo Clinic to Conduct US “VIVA” Trial for Veinplicity
04. Februar 2019 08:00 ET
|
Physeon
SCHAFFHAUSEN, Switzerland, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Physeon GmbH (“Physeon” or the “Company”), a leading developer of medical technology products for venous access, today announced that...
Physeon Positive Clinical Trial Results for its Veinplicity® Device Published in The Journal of Vascular Access
21. Januar 2019 08:00 ET
|
Physeon
SCHAFFHAUSEN, Switzerland, Jan. 21, 2019 (GLOBE NEWSWIRE) -- Physeon GmbH, (“Physeon” or the “Company”), a leading developer of medical technology products for venous access, today announced that...
Physeon Bolsters Management Team with New Appointments
17. Dezember 2018 08:00 ET
|
Physeon
SCHAFFHAUSEN, Switzerland, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Physeon GmbH (“Physeon” or the “Company”), a leading developer of medical technology products for venous access, today announced the...
Physeon Announces Enrollment of First Patient in US “VIVA” Trial for Veinplicity
12. November 2018 09:00 ET
|
Physeon
Important Milestone for Veinplicity Study SCHAFFHAUSEN, Switzerland, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Physeon GmbH (“Physeon” or the “Company”), a leading developer of medical technology...
Physeon Receives Institutional Review Board Approval to Commence US “VIVA” Trial for Veinplicity at Second Site
06. November 2018 09:00 ET
|
Physeon
Recent Clinical Study Indicated Device had a Dilatory Effect 38% Greater than other Common Approaches for Veins Targeted for IV Access. Other studies indicate a First IV Stick Success Much Greater...
Physeon Receives Institutional Review Board Approval to Commence US "VIVA" Trial for Veinplicity
29. Oktober 2018 08:00 ET
|
Physeon
Recent Clinical Study Indicated Device had a Dilatory Effect 38% Greater than other Common Approaches for Veins Targeted for IV Access. Other studies indicate a First IV Stick Success Much Greater...